Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.49 |
| ▸ | HTR7 | P34969 | 12/20 | 0.49 |
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633425 | 0.88 | LTA4H (0.48) | HTR1AHTR7LTA4HKDM1ADRD2 | |
| SCHEMBL13633428 | 0.88 | LTA4H (0.48) | HTR1AHTR7LTA4HKDM1ADRD2 | |
| SCHEMBL13633489 | 0.86 | HTR1A (0.46) | HTR1AHTR7LTA4HKDM1ADRD2 | |
| SCHEMBL13633479 | 0.85 | KCNA5 (0.47) | HTR1AHTR7LTA4HKDM1APOLB | |
| SCHEMBL13404478 | 0.85 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL13404480 | 0.84 | FLT3 (0.49) | SIGMAR1 | |
| SCHEMBL13404508 | 0.82 | NPC1 (0.53) | SIGMAR1POLB | |
| SCHEMBL13404492 | 0.81 | OPRK1 (0.38) | BRD4ATAD2 | |
| SCHEMBL13633486 | 0.81 | KCNA5 (0.51) | HTR1AHTR7LTA4HDRD2HTR6 | |
| SCHEMBL13633474 | 0.81 | HTR1A (0.54) | HTR1AHTR7LTA4HKDM1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | HTR1A 130/4885HTR7 388/4885LTA4H 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.